▴ The humanised monoclonal antibody palivizumab has been developed for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants at high risk; RSV is the most common cause of lower respiratory tract infections in infants.
▴ Palivizumab specifically inhibits an epitope at the A antigenic site of the F protein of RSV subtypes A and B. RSV replication was inhibited in nasal and tracheal aspirates from infants receiving palivizumab 15 mg/kg.
▴ Mean 30-day trough serum concentrations of palivizumab were consistently about 70 mg/L in infants receiving repeated intramuscular or intravenous palivizumab 15 mg/kg. This is above the target serum concentration of 40 mg/L estimated to reduce pulmonary RSV replication by >99% in animal studies.
▴ In a large multicentre trial in 1502 infants at high risk of RSV infection, intramuscular palivizumab 15 mg/kg more than halved the incidence of RSV-attributable hospitalisation to 4.8% compared with 10.6% in placebo recipients.
▴ In the same group of high-risk infants, palivizumab significantly decreased total days in hospital attributable to RSV infection, days with increased supplemental oxygen requirement, days with moderate to severe lower respiratory tract infections and the incidence of admissions to intensive care. It had no effect on the incidence or total number of days of ventilation.
▴ Palivizumab was well tolerated during clinical trials in infants at risk of RSV infection. The incidence of adverse events was similar in placebo (10%) and palivizumab (11%) groups. Fever, irritability and injection site reaction were the most commonly reported adverse events.
KeywordsAdis International Limited Respiratory Syncytial Virus Respiratory Syncytial Virus Infection Haematopoietic Stem Cell Transplantation Palivizumab
Unable to display preview. Download preview PDF.
- 2.Hall CB, McCarthy CA. Respiratory Syncytial Virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious disease. 4th ed. v. 2. New York: Churchill Livingstone Inc., 1995: 1501–19Google Scholar
- 5.Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanised respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial viras in high risk infants: a consensus opinion. Pediatrics 1999; 18: 223–31Google Scholar
- 7.Branco L, Barren P, Gross R, et al. Development of a broadly reactive humanised monoclonal antibody (Mab) for the prevention of severe lower respiratory tract disease caused by respiratory syncytial virus [abstract no.P-57]. In: 17th Annual Meeting of European Society for Pediatric Infectious Diseases.:, 1999Google Scholar
- 10.Piedimonte G, King KA, Holmgren NL, et al. Humanised monoclonal antibody against respiratory syncytial virus (palivizumab) prevents RSV-induced neurogenic inflammation in rat airways [abstract no. 2089]. In: Annual Meeting of the Pediatric Academic Societies; 1999 May 1–4, San FranciscoGoogle Scholar
- 13.Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998 Feb; 17: 110–5PubMedCrossRefGoogle Scholar
- 14.Boeckh M, Bowden RA, Berrey MM, et al. Phase I evaluation of a RSV-specific humanized monoclonal antibody (MEDI-493) after haematopoietic stem cell transplantation [abstract]. 38th International Conference on Antimicrobial Agents and Chemotherapy 1998 Sep 24; 604: 593Google Scholar
- 16.Prevention of respiratory syncytial viras infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102(5): 1211–6Google Scholar